The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tiziana plans switch to US; Vertu ups guidance

Fri, 20th Aug 2021 11:13

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Remote Monitored Systems PLC, up 25% at 0.75 pence, 12-month range 0.36p-5.00p. Reports new Anglo-Indian partnership between its subsidiary Pharm 2 Farm Ltd and India's VKE Enterprises to distribute its Pro-Larva mask. The London-based survey and inspection services provider says Pro-Larva mask is the first anti-viral mask to be approved by the UK Medicines & Healthcare Products Regulatory Agency as a class 1 medical device. The Pro-Larva face mask is made in Britain using patented a-Virion nanotechnology that is clinically proved to kill 99.9% of Covid and Influenza viruses, within 5 minutes of contact, and continues to kill the virus for seven hours, RMS says.

----------

Vertu Motors PLC, up 7.6% at 50.80 pence, 12-month range 24.40p-50.60p. Sees strong used vehicle gross margin retention, due to "exceptional" UK used car market conditions. As a result, expects adjusted pretax profit of no less than GBP50 million in year to August 31, upped from previous guidance between GBP40 million to GBP45 million. "The group's like-for-like new vehicle order take for the key month of September is currently running in excess of prior year levels, however, there is a risk that well documented new vehicle supply shortages will result in vehicle deliveries being delayed into future periods. As a consequence of reduced new vehicle supply, used vehicle supply may also be restricted in the coming months," company adds.

----------

AIM - LOSERS

----------

Amur Minerals Corp, down 11% at 2.18 pence, 12-month range 1.30p-2.90p. Notes permanent conditions report on its far east Russia Kun-Manie nickel copper sulfide project completed. It shows the nickel cutoff grade is calculated to be 0.3% nickel. Revenue is based on a presently conservative nickel price of USD13,300 per tonne and a copper price of USD5,960 per tonne. Metal recoveries are anticipated to be 74% for nickel and 52% for copper. Mine ore production and the nominal mill throughput at six million tonnes per annum indicates a potential mine life in the order of 25 years. The report says the reserve base is substantial and suitable to potentially sustain an 11.2 million tonne per year throughput

----------

Tiziana Life Sciences PLC, down 12% at 51.08 pence, 12-month range 51.08p-204.00p. Formally starts strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, as the ultimate parent company of the Tiziana group. Shares will be swapped for shares in the new parent company, which will then be listed in the US on Nasdaq. As a result, Tiziana to be delisted in London. "The interests of its business and shareholders are best served by aligning the place of the listing with the principal business activities of the Tiziana group, which are predominately based in the US," company explains.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2019 11:40

Tiziana Life Sciences Non-Exec Director Riccardo Dalla-Favera Resigns

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday said Non-Executive Director Riccardo Dalla-Favera has resigned from his role."The company is grateful to Favera for his

Read more
3 Dec 2018 14:27

Tiziana completes patient enrolment in ongoing Milciclib study

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that patient enrolment in its ongoing Phase 2a clinical trial, known as CDKO-125A-010, was now completed.

Read more
3 Dec 2018 11:51

Tiziana Life Completes Patient Enrollment In Liver Cancer Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.The company explained that the

Read more
28 Nov 2018 12:19

Tiziana Life Sciences Begins First-In-Human Phase 1 Trial Of Foralumab

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it began the first in-human trial of Foralumab, a treatment for autoimmune diseases.The biotechnology company said the a

Read more
20 Nov 2018 12:53

Tiziana Life Sciences Prices ADS Offering, Raises GBP3.4 Million

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has priced its underwritten public offering in the US of 442,910 American Depositary Shares representing ordinary shares in

Read more
25 Sep 2018 13:43

Tiziana Life Seeks Listing Of ADS On Nasdaq Capital Market (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has commenced underwritten public offering in the US of American Depositary Shares representing ordinary shares in the UK of

Read more
24 Sep 2018 12:37

Tiziana Half-Year Loss Unchanged; Gets US Approval For Foralumab Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday reported a flat loss in the first half of 2018 as expenses were broadly unchanged, while the biotechnology firm also announced that its

Read more
17 Aug 2018 11:39

DIRECTOR DEALINGS: Tiziana Life Chairman Associate Buys Shares

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday that Panetta Partners Ltd, a company associated with Chairman Gabriele Cerrone, bought shares in the company worth acquired 469,766 a

Read more
16 Aug 2018 11:47

Tiziana seeks trial for multiple sclerosis 'game changer'

(Sharecast News) - Tiziana Life Sciences on Thursday submitted an application to initiate phase one clinical trials for a new treatment of neurodegenerative diseases to the US food and drug administration.

Read more
27 Jul 2018 11:14

Tiziana Life Sciences Files For IPO Of American Depositary Shares (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday it filed a registration statement with the US Securities Exchange Commission for a proposed initial public offering of its American

Read more
16 May 2018 13:27

Tiziana Life Science Reports Progress In Milcicib Phase 2a Trial

LONDON (Alliance News) - Biotechnology company Tiziana Life Sciences PLC said Wednesday that the phase 2a trial of Milciclib safety and tolerability in patients with Metastatic Hepatocellular has

Read more
19 Apr 2018 14:44

Tiziana Raises GBP825,000 Through Placing Of 1 Million Shares (ALLISS)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Thursday it has raised GBP825,000 from the issue of 1.0 million new shares at a price of 80 pence per share.The cancer and autoimmune

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
16 Nov 2016 09:34

Tiziana Life Sciences makes breakthrough oral treatment for inflammatory diseases

(ShareCast News) - Tiziana Life Sciences, the clinical stage biotechnology company, announced that new data has demonstrated the potential of its novel oral therapy with foralumab for non-alcoholic steatohepatitis (NASH), diabetes and other life threatening inflammatory diseases. Oral efficacy in hu

Read more
18 Jul 2016 12:03

Tiziana Life looks for secrets of long life with new acquisition

(ShareCast News) - Tiziana Life Sciences has purchased key assets from Sardinia-based biobanking and genomics research company Shardna for ā‚¬258,000, giving it access to the genetic data of nearly 13,000 people from the Ogliastra region, where life expectancy is high. The AIM-listed clinical stage bi

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.